论文部分内容阅读
《全反式维甲酸与三氧化二砷治疗恶性血液疾病的分子机制研究》第一完成人是上海第二医科大学附属瑞金医院血液科副主任、上海血液研究所副所长陈赛娟教授。该研究主要是倡导了诱导分化、凋亡疗法,在临床上应用“全反式维甲酸”、“三氧化二砷”(俗称砒霜)治疗一种十分凶险的急性早幼粒细胞白血病,并在基础研究中摸清了其作用机理。所谓“诱导分化、调亡疗法”,它不同于治疗癌症中的化疗、放疗,在杀死癌细胞的同时也导致正常细胞死亡或损伤。这种疗法是通过“教育、改造”癌细胞,使其转变为正常细胞;让癌细胞在药物的作
“All-trans retinoic acid and arsenic trioxide in the treatment of malignant hematological diseases,” the first person to complete the Shanghai Second Medical University Affiliated Ruijin Hospital, deputy director of the Department of Hematology, Shanghai Institute of Blood Professor Chen Sai-Juan, deputy director. This study mainly advocates the induction of differentiation and apoptosis therapy. In the clinical application of “all-trans retinoic acid” and “arsenic trioxide” (arsenic trioxide) in the treatment of a very dangerous acute promyelocytic leukemia, and in basic research Find out its mechanism of action. The so-called “induction of differentiation, apoptosis therapy”, which is different from the treatment of cancer chemotherapy, radiotherapy, while killing cancer cells but also lead to normal cell death or injury. This therapy is through “education, transformation” of cancer cells, making it into normal cells; so that cancer cells in the drug for